文献速递其他结缔组织病

血浆置换治疗抗SRP抗体阳性难治性炎性肌病病例系列

Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

治疗后3周88.9%(8/9)患者达到2016年ACR/EULAR肌炎反应标准改善,其中55.6%(5/9)为轻微改善、33.3%(3/9)为中度改善。研究认为PE对抗SRP抗体阳性难治性IIM有效,可作为对糖皮质激素联合免疫抑制剂抵抗患者的替代治疗。

要点

  • PE后3周88.9%(8/9)抗SRP抗体阳性难治性IIM患者达到2016年ACR/EULAR反应标准改善。
  • 改善者中55.6%(5/9)为轻微改善、33.3%(3/9)为中度改善。
  • 4例合并间质性肺病患者胸部CT示磨玻璃影及不规则线状影消退,4例下肢MRI示肌肉水肿减轻。

核心结论

  • 血浆置换对抗SRP抗体阳性的难治性特发性炎性肌病患者有效,可考虑作为对糖皮质激素联合免疫抑制剂治疗抵抗者的替代治疗。

研究设计与样本

  • 比较PE治疗前后的临床表现、实验室检查、胸部CT和下肢MRI,并用2016年ACR/EULAR肌炎反应标准评估治疗反应。

主要发现

  • PE治疗后3周88.9%(8/9)患者达到改善,其中55.6%(5/9)为轻微改善、33.3%(3/9)为中度改善。
  • 基线至PE后3周,医师总体活动度、患者总体活动度、HAQ、徒手肌力测试(MMT)、肌肉外疾病活动度及肌酶(CK、LDH、AST)差异有统计学意义,ALT除外。
  • 4例合并间质性肺病患者PE后胸部CT示磨玻璃影和不规则线状影消退,4例下肢MRI示肌肉水肿减轻。

关键数值与推荐

  • 治疗反应采用2016年ACR/EULAR肌炎反应标准评估,改善分为轻微改善与中度改善。
  • PE后3周总体改善率为88.9%(8/9),轻微改善55.6%(5/9),中度改善33.3%(3/9)。

临床怎么用

  • 对糖皮质激素联合免疫抑制剂抵抗的抗SRP抗体阳性难治性IIM患者,可考虑血浆置换作为替代治疗选择。
  • 疗效评估可结合2016年ACR/EULAR肌炎反应标准及核心指标(医师/患者总体活动度、HAQ、MMT、肌肉外疾病活动度、肌酶)。
  • 合并间质性肺病或肌肉水肿者可用胸部CT和下肢MRI辅助随访。

局限性

  • 为单中心病例系列,样本量仅9例,无对照组,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody. METHODS: Nine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE therapy at Ruijin Hospital from October 2017 to December 2020. The clinical manifestations, laboratory tests, chest CT and lower extremity MRI images before and after PE therapy were compared. The treatment response was evaluated by the 2016 ACR/EULAR myositis response criteria. RESULTS: A total of 88.9% (8/9) of subjects had achieved improvement by 3 weeks after PE therapy, with 55.6% (5/9) minimal improvement and 33.3% (3/9) moderate improvement. There were statistically significant improvements between baseline and after PE therapy at 3 weeks on the core set measures: physician global activity, patient global activity, HAQ, manual muscle testing (MMT), extramuscular disease activity, and muscle enzymes activity including creatine kinase (CK), lactate dehydrogenase (LDH), aspartate transaminase (AST), except for alanine transaminase (ALT). Moreover, the chest CT showed regression of ground glass opacities and irregular linear opacities after PE therapy in four patients with interstitial lung disease. The MRI images of lower extremity in four patients showed reduction of muscle oedema after the therapy. CONCLUSION: PE therapy is effective for refractory IIM patients with positive anti-SRP antibody. It should be considered as an alternative treatment for those patients who are resistant to the combined therapy of glucocorticoids and immunosuppressive agents.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Zhang H, Sun Y, Liu H, et al. Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series. Rheumatology (Oxford). 2022. PMID: 34508561. doi:10.1093/rheumatology/keab629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。